PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT

Submitted: 10 January 2012
Accepted: 10 January 2012
Published: 10 January 2012
Abstract Views: 775
PDF: 1219
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Chronic myelogenous leukemia (CML) is characterized by a clonal expansion of a hematopoietic stem cell possessing a reciprocal translocation between chromosomes 9 and 22, the Philadelphia chromosome, as identified cytogenetically or molecularly (RT-PCR). CML accounts for 15% of adult leukemias. The disease progresses from a chronic phase through an accelerated phase to a blast phase. In the past, the National Comprehensive Cancer Network had suggested that there were three primary treatments available for CML which included: allogeneic bone marrow transplantation (BMT), IFN-α with or without cytarabine, and imatinib mesylate (Glivec®). It has been shown that Glivec is superior to the combination of interferon plus cytarabine. Although BMT can be a curative treatment for CML it is not usually used as a front-line therapy, due to limited donor availability and high toxicity of the procedure. Five-year survival rates following HLA-matched transplants are approximately 75% for patients in chronic phase.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Defina, M., Bocchia, M., Ippoliti, I., Gozzetti, A., Calabrese, S., Crupi, R., Chitarrelli, I., & Lauria, F. (2012). PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT. Journal of the Siena Academy of Sciences, 1(1), 15–17. https://doi.org/10.4081/jsas.2009.329